{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:22:09Z","timestamp":1792606929175,"version":"4.5.0"},"reference-count":197,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,9,2]],"date-time":"2014-09-02T00:00:00Z","timestamp":1409616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,9,2]],"date-time":"2014-09-02T00:00:00Z","timestamp":1409616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1038\/nrendo.2014.155","type":"journal-article","created":{"date-parts":[[2014,9,2]],"date-time":"2014-09-02T07:36:16Z","timestamp":1409643376000},"page":"659-672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Novel metabolic biomarkers of cardiovascular disease"],"prefix":"10.1038","volume":"10","author":[{"given":"Majken K.","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica L.","family":"Bertoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah E.","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric B.","family":"Rimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Mukamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,2]]},"reference":[{"key":"BFnrendo2014155_CR1","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1161\/CIR.0b013e318245fac5","volume":"125","author":"VL Roger","year":"2012","unstructured":"Roger, V. L.  et al. Heart disease and stroke statistics\u20142012 update: a report from the American Heart Association. Circulation 125, e2\u2013e220 (2012).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.7326\/0003-4819-132-10-200005160-00002","volume":"132","author":"LA Prosser","year":"2000","unstructured":"Prosser, L. A.  et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann. Intern. Med. 132, 769\u2013779 (2000).","journal-title":"Ann. Intern. Med."},{"key":"BFnrendo2014155_CR3","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","volume":"129","author":"DC Goff","year":"2014","unstructured":"Goff, D. C.  et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation 129, S49\u2013S73 (2014).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1161\/01.CIR.0000055014.62083.05","volume":"107","author":"PM Ridker","year":"2003","unstructured":"Ridker, P. M., Buring, J. E., Cook, N. R. & Rifai, N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107, 391\u2013397 (2003).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR5","unstructured":"NIH. Third report of the National Cholesterol Education Program (NECP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report [online], (2004)."},{"key":"BFnrendo2014155_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","volume":"62","author":"T Gordon","year":"1977","unstructured":"Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B. & Dawber, T. R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62, 707\u2013714 (1977).","journal-title":"Am. J. Med."},{"key":"BFnrendo2014155_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0140-6736(08)61076-4","volume":"372","author":"MJ McQueen","year":"2008","unstructured":"McQueen, M. J.  et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case\u2013control study. Lancet 372, 224\u2013233 (2008).","journal-title":"Lancet"},{"key":"BFnrendo2014155_CR8","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"E Di Angelantonio","year":"2009","unstructured":"Di Angelantonio, E.  et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993\u20132000 (2009).","journal-title":"JAMA"},{"key":"BFnrendo2014155_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","volume":"4","author":"AD Sniderman","year":"2011","unstructured":"Sniderman, A. D.  et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ. Cardiovasc. Qual. Outcomes 4, 337\u2013345 (2011).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"BFnrendo2014155_CR10","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1161\/01.CIR.0000041255.88750.F0","volume":"106","author":"R Corti","year":"2002","unstructured":"Corti, R.  et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 106, 2884\u20132887 (2002).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"SM Grundy","year":"2004","unstructured":"Grundy, S. M.  et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227\u2013239 (2004).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.atherosclerosis.2011.04.005","volume":"218","author":"AM West","year":"2011","unstructured":"West, A. M.  et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis 218, 156\u2013162 (2011).","journal-title":"Atherosclerosis"},{"key":"BFnrendo2014155_CR13","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.ahj.2008.07.023","volume":"156","author":"CP Cannon","year":"2008","unstructured":"Cannon, C. P.  et al. Rationale and design of IMPROVE\u2013IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am. Heart J. 156, 826\u2013832 (2008).","journal-title":"Am. Heart J."},{"key":"BFnrendo2014155_CR14","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1161\/CIRCULATIONAHA.106.667428","volume":"117","author":"HR Superko","year":"2008","unstructured":"Superko, H. R. & King, S. III. Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 117, 560\u2013568 (2008).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.107.720300","volume":"117","author":"SM Grundy","year":"2008","unstructured":"Grundy, S. M. Promise of low-density lipoprotein-lowering therapy for primary and secondary prevention. Circulation 117, 569\u2013573 (2008).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR16","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.cll.2006.07.002","volume":"26","author":"E Anuurad","year":"2006","unstructured":"Anuurad, E., Boffa, M. B., Koschinsky, M. L. & Berglund, L. Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin. Lab. Med. 26, 751\u2013772 (2006).","journal-title":"Clin. Lab. Med."},{"key":"BFnrendo2014155_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00041433-199906000-00005","volume":"10","author":"HH Hobbs","year":"1999","unstructured":"Hobbs, H. H. & White, A. L. Lipoprotein(a): intrigues and insights. Curr. Opin. Lipidol. 10, 225\u2013236 (1999).","journal-title":"Curr. Opin. Lipidol."},{"key":"BFnrendo2014155_CR18","doi-asserted-by":"publisher","first-page":"57U","DOI":"10.1016\/S0002-9149(98)00954-0","volume":"82","author":"SM Marcovina","year":"1998","unstructured":"Marcovina, S. M. & Koschinsky, M. L. Lipoprotein(a) as a risk factor for coronary artery disease. Am. J. Cardiol. 82, 57U\u201366U (1998).","journal-title":"Am. J. Cardiol."},{"key":"BFnrendo2014155_CR19","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1161\/01.CIR.96.8.2514","volume":"96","author":"M Poon","year":"1997","unstructured":"Poon, M., Zhang, X., Dunsky, K. G., Taubman, M. B. & Harpel, P. C. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 96, 2514\u20132519 (1997).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1161\/01.ATV.17.5.905","volume":"17","author":"LB Nielsen","year":"1997","unstructured":"Nielsen, L. B., Gronholdt, M. L., Schroeder, T. V., Stender, S. & Nordestgaard, B. G. In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler. Thromb. Vasc. Biol. 17, 905\u2013911 (1997).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrendo2014155_CR21","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jacc.2012.01.078","volume":"60","author":"A Helgadottir","year":"2012","unstructured":"Helgadottir, A.  et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J. Am. Coll. Cardiol. 60, 722\u2013729 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrendo2014155_CR22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1161\/01.ATV.18.4.641","volume":"18","author":"LB Nielsen","year":"1998","unstructured":"Nielsen, L. B., Juul, K. & Nordestgaard, B. G. Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima\u2013inner media of rabbits: in vivo evidence that lipoprotein(a) may contribute to foam cell formation. Arterioscler. Thromb. Vasc. Biol. 18, 641\u2013649 (1998).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrendo2014155_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jth.12056","volume":"11","author":"JS Danik","year":"2013","unstructured":"Danik, J. S.  et al. Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21,483 women. J. Thromb. Haemost. 11, 205\u2013208 (2013).","journal-title":"J. Thromb. Haemost."},{"key":"BFnrendo2014155_CR24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"S Erqou","year":"2009","unstructured":"Erqou, S.  et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302, 412\u2013423 (2009).","journal-title":"JAMA"},{"key":"BFnrendo2014155_CR25","doi-asserted-by":"publisher","first-page":"3478a","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard, B. G.  et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 34, 3478a\u20133490a (2013).","journal-title":"Eur. Heart J."},{"key":"BFnrendo2014155_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1172\/JCI115855","volume":"90","author":"E Boerwinkle","year":"1992","unstructured":"Boerwinkle, E.  et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J. Clin. Invest. 90, 52\u201360 (1992).","journal-title":"J. Clin. Invest."},{"key":"BFnrendo2014155_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1086\/514851","volume":"61","author":"V Mooser","year":"1997","unstructured":"Mooser, V.  et al. The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans. Am. J. Hum. Genet. 61, 402\u2013417 (1997).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrendo2014155_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/ng.314","volume":"41","author":"DA Tregouet","year":"2009","unstructured":"Tregouet, D. A.  et al. Genome-wide haplotype association study identifies the SLC22A3\u2013LPAL2\u2013LPA gene cluster as a risk locus for coronary artery disease. Nat. Genet. 41, 283\u2013285 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrendo2014155_CR29","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","volume":"301","author":"PR Kamstrup","year":"2009","unstructured":"Kamstrup, P. R., Tybjaerg-Hansen, A., Steffensen, R. & Nordestgaard, B. G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301, 2331\u20132339 (2009).","journal-title":"JAMA"},{"key":"BFnrendo2014155_CR30","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1161\/01.CIR.0000048125.79640.77","volume":"107","author":"SR Holmer","year":"2003","unstructured":"Holmer, S. R.  et al. Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. Circulation 107, 696\u2013701 (2003).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR31","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archinte.164.10.1121","volume":"164","author":"W Insull Jr","year":"2004","unstructured":"Insull, W. Jr  et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch. Intern. Med. 164, 1121\u20131127 (2004).","journal-title":"Arch. Intern. Med."},{"key":"BFnrendo2014155_CR32","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","volume":"62","author":"JJ Albers","year":"2013","unstructured":"Albers, J. J.  et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM\u2013HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL\/High Triglyceride and Impact on Global Health Outcomes). J. Am. Coll. Cardiol. 62, 1575\u20131579 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrendo2014155_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00380-013-0367-5","volume":"29","author":"U Bregar","year":"2013","unstructured":"Bregar, U., Jug, B., Keber, I., Cevc, M. & Sebestjen, M. Extended-release niacin\/laropiprant improves endothelial function in patients after myocardial infarction. Heart Vessels 29, 313\u2013319 (2013).","journal-title":"Heart Vessels"},{"key":"BFnrendo2014155_CR34","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2009.12.023","volume":"210","author":"E Bruckert","year":"2010","unstructured":"Bruckert, E., Labreuche, J. & Amarenco, P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210, 353\u2013361 (2010).","journal-title":"Atherosclerosis"},{"key":"BFnrendo2014155_CR35","doi-asserted-by":"crossref","unstructured":"HSP2\u2013THRIVE Collaborative Group. HPS2\u2013THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 34, 1279\u20131291 (2013).","DOI":"10.1093\/eurheartj\/eht055"},{"key":"BFnrendo2014155_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijcard.2011.09.060","volume":"154","author":"H Takagi","year":"2012","unstructured":"Takagi, H. & Umemoto, T. Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials. Int. J. Cardiol. 154, 183\u2013186 (2012).","journal-title":"Int. J. Cardiol."},{"key":"BFnrendo2014155_CR37","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.1995.03530220037029","volume":"274","author":"VM Maher","year":"1995","unstructured":"Maher, V. M.  et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 274, 1771\u20131774 (1995).","journal-title":"JAMA"},{"key":"BFnrendo2014155_CR38","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1399-0004.1997.tb04342.x","volume":"52","author":"K Berg","year":"1997","unstructured":"Berg, K.  et al. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin. Genet. 52, 254\u2013261 (1997).","journal-title":"Clin. Genet."},{"key":"BFnrendo2014155_CR39","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.jacc.2010.10.052","volume":"57","author":"E Merki","year":"2011","unstructured":"Merki, E.  et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J. Am. Coll. Cardiol. 57, 1611\u20131621 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrendo2014155_CR40","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.108.786822","volume":"118","author":"E Merki","year":"2008","unstructured":"Merki, E.  et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 118, 743\u2013753 (2008).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR41","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/MOL.0b013e3283598d81","volume":"23","author":"B Kolski","year":"2012","unstructured":"Kolski, B. & Tsimikas, S. Emerging therapeutic agents to lower lipoprotein (a) levels. Curr. Opin. Lipidol. 23, 560\u2013568 (2012).","journal-title":"Curr. Opin. Lipidol."},{"key":"BFnrendo2014155_CR42","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2217\/bmm.11.60","volume":"5","author":"A Taleb","year":"2011","unstructured":"Taleb, A., Witztum, J. L. & Tsimikas, S. Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark. Med. 5, 673\u2013694 (2011).","journal-title":"Biomark. Med."},{"key":"BFnrendo2014155_CR43","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/j.jacc.2013.02.047","volume":"61","author":"ML Bertoia","year":"2013","unstructured":"Bertoia, M. L.  et al. Oxidation-specific biomarkers and risk of peripheral artery disease. J. Am. Coll. Cardiol. 61, 2169\u20132179 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrendo2014155_CR44","first-page":"115","volume":"21","author":"S Ozkanlar","year":"2012","unstructured":"Ozkanlar, S. & Akcay, F. Antioxidant vitamins in atherosclerosis\u2014animal experiments and clinical studies. Adv. Clin. Exp. Med. 21, 115\u2013123 (2012).","journal-title":"Adv. Clin. Exp. Med."},{"key":"BFnrendo2014155_CR45","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.bbalip.2006.07.011","volume":"1761","author":"RH Schaloske","year":"2006","unstructured":"Schaloske, R. H. & Dennis, E. A. The phospholipase A2 superfamily and its group numbering system. Biochim. Biophys. Acta 1761, 1246\u20131259 (2006).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrendo2014155_CR46","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1006\/bbrc.1999.1066","volume":"261","author":"K Asano","year":"1999","unstructured":"Asano, K.  et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem. Biophys. Res. Commun. 261, 511\u2013514 (1999).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrendo2014155_CR47","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1161\/hq0202.102918","volume":"22","author":"V Tsimihodimos","year":"2002","unstructured":"Tsimihodimos, V.  et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler. Thromb. Vasc. Biol. 22, 306\u2013311 (2002).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrendo2014155_CR48","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1016\/S0021-9258(18)61336-5","volume":"262","author":"DM Stafforini","year":"1987","unstructured":"Stafforini, D. M., Prescott, S. M. & McIntyre, T. M. Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J. Biol. Chem. 262, 4223\u20134230 (1987).","journal-title":"J. Biol. Chem."},{"key":"BFnrendo2014155_CR49","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1161\/01.ATV.0000160551.21962.a7","volume":"25","author":"A Zalewski","year":"2005","unstructured":"Zalewski, A. & Macphee, C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler. Thromb. Vasc. Biol. 25, 923\u2013931 (2005).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrendo2014155_CR50","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1194\/jlr.R024190","volume":"53","author":"RS Rosenson","year":"2012","unstructured":"Rosenson, R. S. & Stafforini, D. M. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J. Lipid Res. 53, 1767\u20131782 (2012).","journal-title":"J. Lipid Res."},{"key":"BFnrendo2014155_CR51","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3109\/1354750X.2012.664170","volume":"17","author":"O Vittos","year":"2012","unstructured":"Vittos, O., Toana, B., Vittos, A. & Moldoveanu, E. Lipoprotein-associated phospholipase A2 (Lp\u2013PLA2): a review of its role and significance as a cardiovascular biomarker. Biomarkers 17, 289\u2013302 (2012).","journal-title":"Biomarkers"},{"key":"BFnrendo2014155_CR52","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2217\/14796678.5.2.159","volume":"5","author":"M Ali","year":"2009","unstructured":"Ali, M. & Madjid, M. Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target. Future Cardiol. 5, 159\u2013173 (2009).","journal-title":"Future Cardiol."},{"key":"BFnrendo2014155_CR53","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.cll.2006.06.003","volume":"26","author":"JP McConnell","year":"2006","unstructured":"McConnell, J. P. & Hoefner, D. M. Lipoprotein-associated phospholipase A2. Clin. Lab. Med. 26, 679\u2013697 (2006).","journal-title":"Clin. Lab. Med."},{"key":"BFnrendo2014155_CR54","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1161\/CIRCULATIONAHA.110.936393","volume":"122","author":"Z Mallat","year":"2010","unstructured":"Mallat, Z., Lambeau, G. & Tedgui, A. Lipoprotein-associated and secreted phospholipases A(2) in cardiovascular disease: roles as biological effectors and biomarkers. Circulation 122, 2183\u20132200 (2010).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR55","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.jacc.2007.11.079","volume":"51","author":"ER Mohler III","year":"2008","unstructured":"Mohler, E. R. III  et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 51, 1632\u20131641 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrendo2014155_CR56","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","volume":"370","author":"HD White","year":"2014","unstructured":"White, H. D.  et al. Darapladib for preventing ischemic events in stable coronary heart disease. N. Engl. J. Med. 370, 1702\u20131711 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2014155_CR57","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1161\/CIRCULATIONAHA.113.000962","volume":"128","author":"RS Rosenson","year":"2013","unstructured":"Rosenson, R. S.  et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation 128, 1256\u20131267 (2013).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR58","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1373\/clinchem.2007.101923","volume":"54","author":"R Movva","year":"2008","unstructured":"Movva, R. & Rader, D. J. Laboratory assessment of HDL heterogeneity and function. Clin. Chem. 54, 788\u2013800 (2008).","journal-title":"Clin. Chem."},{"key":"BFnrendo2014155_CR59","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1056\/NEJMoa070635","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen, S. E.  et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304\u20131316 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2014155_CR60","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter, P. J.  et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109\u20132122 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2014155_CR61","doi-asserted-by":"publisher","first-page":"b92","DOI":"10.1136\/bmj.b92","volume":"338","author":"M Briel","year":"2009","unstructured":"Briel, M.  et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338, b92 (2009).","journal-title":"BMJ"},{"key":"BFnrendo2014155_CR62","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1126\/science.1142447","volume":"316","author":"R McPherson","year":"2007","unstructured":"McPherson, R.  et al. A common allele on chromosome 9 associated with coronary heart disease. Science 316, 1488\u20131491 (2007).","journal-title":"Science"},{"key":"BFnrendo2014155_CR63","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng.76","volume":"40","author":"CJ Willer","year":"2008","unstructured":"Willer, C. J.  et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40, 161\u2013169 (2008).","journal-title":"Nat. Genet."},{"key":"BFnrendo2014155_CR64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/ng.269","volume":"41","author":"YS Aulchenko","year":"2009","unstructured":"Aulchenko, Y. S.  et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat. Genet. 41, 47\u201355 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrendo2014155_CR65","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight, B. F.  et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380, 572\u2013580 (2012).","journal-title":"Lancet"},{"key":"BFnrendo2014155_CR66","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.atherosclerosis.2007.08.009","volume":"197","author":"JA de Souza","year":"2008","unstructured":"de Souza, J. A.  et al. Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis 197, 84\u201394 (2008).","journal-title":"Atherosclerosis"},{"key":"BFnrendo2014155_CR67","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.metabol.2009.05.004","volume":"58","author":"A Onat","year":"2009","unstructured":"Onat, A., Can., G., Ayhan, E., Kaya, Z. & Hergenc, G. Impaired protection against diabetes and coronary heart disease by high-density lipoproteins in Turks. Metabolism 58, 1393\u20131399 (2009).","journal-title":"Metabolism"},{"key":"BFnrendo2014155_CR68","doi-asserted-by":"publisher","first-page":"e000519","DOI":"10.1161\/JAHA.113.000519","volume":"3","author":"JT Wilkins","year":"2014","unstructured":"Wilkins, J. T.  et al. Coronary heart disease risks associated with high levels of HDL cholesterol. J. Am. Heart Assoc. 3, e000519 (2014).","journal-title":"J. Am. Heart Assoc."},{"key":"BFnrendo2014155_CR69","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa1001689","volume":"364","author":"AV Khera","year":"2011","unstructured":"Khera, A. V.  et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127\u2013135 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2014155_CR70","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1161\/ATVBAHA.113.301373","volume":"33","author":"XM Li","year":"2013","unstructured":"Li, X. M.  et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler. Thromb. Vasc. Biol. 33, 1696\u20131705 (2013).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrendo2014155_CR71","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1161\/01.ATV.0000146325.93749.a8","volume":"24","author":"BF Asztalos","year":"2004","unstructured":"Asztalos, B. F.  et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol. 24, 2181\u20132187 (2004).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrendo2014155_CR72","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1161\/CIRCULATIONAHA.108.816181","volume":"119","author":"S Mora","year":"2009","unstructured":"Mora, S.  et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 119, 931\u2013939 (2009).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR73","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1161\/CIRCULATIONAHA.111.073684","volume":"125","author":"S Parish","year":"2012","unstructured":"Parish, S.  et al. Lipids and lipoproteins and risk of different vascular events in the MRC\/BHF Heart Protection Study. Circulation 125, 2469\u20132478 (2012).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR74","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1056\/NEJM199108083250601","volume":"325","author":"MJ Stampfer","year":"1991","unstructured":"Stampfer, M. J., Sacks, F. M., Salvini, S., Willett, W. C. & Hennekens, C. H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N. Engl. J. Med. 325, 373\u2013381 (1991).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2014155_CR75","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.atherosclerosis.2010.10.024","volume":"214","author":"PT Williams","year":"2011","unstructured":"Williams, P. T. & Feldman, D. E. Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort. Atherosclerosis 214, 196\u2013202 (2011).","journal-title":"Atherosclerosis"},{"key":"BFnrendo2014155_CR76","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jacc.2007.09.060","volume":"51","author":"WA van der Steeg","year":"2008","unstructured":"van der Steeg, W. A.  et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll.Cardiol. 51, 634\u2013642 (2008).","journal-title":"J. Am. Coll.Cardiol."},{"key":"BFnrendo2014155_CR77","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","volume":"367","author":"GG Schwartz","year":"2012","unstructured":"Schwartz, G. G.  et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089\u20132099 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2014155_CR78","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJM199908053410604","volume":"341","author":"HB Rubins","year":"1999","unstructured":"Rubins, H. B.  et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341, 410\u2013418 (1999).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2014155_CR79","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1161\/01.ATV.0000183727.90611.4f","volume":"25","author":"BF Asztalos","year":"2005","unstructured":"Asztalos, B. F.  et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler. Thromb. Vasc. Biol. 25, 2185\u20132191 (2005).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrendo2014155_CR80","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.metabol.2007.08.009","volume":"57","author":"BF Asztalos","year":"2008","unstructured":"Asztalos, B. F.  et al. Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Metabolism 57, 77\u201383 (2008).","journal-title":"Metabolism"},{"key":"BFnrendo2014155_CR81","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0076-6879(96)63004-3","volume":"263","author":"P Alaupovic","year":"1996","unstructured":"Alaupovic, P. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Methods Enzymol. 263, 32\u201360 (1996).","journal-title":"Methods Enzymol."},{"key":"BFnrendo2014155_CR82","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1194\/jlr.R035725","volume":"54","author":"AS Shah","year":"2013","unstructured":"Shah, A. S., Tan, L., Long, J. L. & Davidson, W. S. Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J. Lipid Res. 54, 2575\u20132585 (2013).","journal-title":"J. Lipid Res."},{"key":"BFnrendo2014155_CR83","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nm.3459","volume":"20","author":"Y Huang","year":"2014","unstructured":"Huang, Y.  et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat. Med. 20, 193\u2013203 (2014).","journal-title":"Nat. Med."},{"key":"BFnrendo2014155_CR84","doi-asserted-by":"publisher","first-page":"jah3","DOI":"10.1161\/JAHA.111.000232","volume":"1","author":"MK Jensen","year":"2012","unstructured":"Jensen, M. K., Rimm, E. B., Furtado, J. D. & Sacks, F. M. Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease. J. Am. Heart Assoc. 1, jah3\u2013e000232 (2012).","journal-title":"J. Am. Heart Assoc."},{"key":"BFnrendo2014155_CR85","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1161\/CIRCULATIONAHA.111.056986","volume":"124","author":"CO Mendivil","year":"2011","unstructured":"Mendivil, C. O., Rimm, E. B., Furtado, J., Chiuve, S. E. & Sacks, F. M. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation 124, 2065\u20132072 (2011).","journal-title":"Circulation"},{"issue":"Suppl. 12","key":"BFnrendo2014155_CR86","first-page":"A023","volume":"127","author":"MK Jensen","year":"2013","unstructured":"Jensen, M. K., Furtado, J. D., Rimm, E. B., Sacks, F. M. & Overvad, K. Presence of apolipoprotein C-III defines a high density lipoprotein subtype that is not inversely associated with incident coronary events [abstract 023]. Circulation 127 (Suppl. 12), A023 (2013).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR87","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1161\/CIRCULATIONAHA.105.591743","volume":"113","author":"A Kawakami","year":"2006","unstructured":"Kawakami, A.  et al. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 113, 691\u2013700 (2006).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR88","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","volume":"112","author":"MJ Graham","year":"2013","unstructured":"Graham, M. J.  et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ. Res. 112, 1479\u20131490 (2013).","journal-title":"Circ. Res."},{"key":"BFnrendo2014155_CR89","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ahj.2004.02.004","volume":"148","author":"A Splaver","year":"2004","unstructured":"Splaver, A., Lamas, G. A. & Hennekens, C. H. Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials. Am. Heart J. 148, 34\u201340 (2004).","journal-title":"Am. Heart J."},{"key":"BFnrendo2014155_CR90","first-page":"111","volume":"56","author":"KS McCully","year":"1969","unstructured":"McCully, K. S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am. J. Pathol. 56, 111\u2013128 (1969).","journal-title":"Am. J. Pathol."},{"key":"BFnrendo2014155_CR91","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/jama.1995.03530130055028","volume":"274","author":"CJ Boushey","year":"1995","unstructured":"Boushey, C. J., Beresford, S. A., Omenn, G. S. & Motulsky, A. G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274, 1049\u20131057 (1995).","journal-title":"JAMA"},{"key":"BFnrendo2014155_CR92","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1161\/CIRCULATIONAHA.105.570846","volume":"113","author":"Q Yang","year":"2006","unstructured":"Yang, Q.  et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 113, 1335\u20131343 (2006).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR93","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1079\/PNS2004390","volume":"63","author":"JJ Strain","year":"2004","unstructured":"Strain, J. J., Dowey, L., Ward, M., Pentieva, K. & McNulty, H. B-vitamins, homocysteine metabolism and CVD. Proc. Nutr. Soc. 63, 597\u2013603 (2004).","journal-title":"Proc. Nutr. Soc."},{"key":"BFnrendo2014155_CR94","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1001\/archinternmed.2010.348","volume":"170","author":"R Clarke","year":"2010","unstructured":"Clarke, R.  et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37,485 individuals. Arch. Intern. Med. 170, 1622\u20131631 (2010).","journal-title":"Arch. Intern. Med."},{"key":"BFnrendo2014155_CR95","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/S0140-6736(07)60854-X","volume":"369","author":"X Wang","year":"2007","unstructured":"Wang, X.  et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369, 1876\u20131882 (2007).","journal-title":"Lancet"},{"key":"BFnrendo2014155_CR96","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1161\/STROKEAHA.108.529503","volume":"40","author":"G Saposnik","year":"2009","unstructured":"Saposnik, G., Ray, J. G., Sheridan, P., McQueen, M. & Lonn, E. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 40, 1365\u20131372 (2009).","journal-title":"Stroke"},{"key":"BFnrendo2014155_CR97","doi-asserted-by":"publisher","first-page":"315","DOI":"10.7326\/0003-4819-152-5-201003020-00010","volume":"152","author":"L Wang","year":"2010","unstructured":"Wang, L., Manson, J. E., Song, Y. & Sesso, H. D. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann. Intern. Med. 152, 315\u2013323 (2010).","journal-title":"Ann. Intern. Med."},{"key":"BFnrendo2014155_CR98","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/ajcn\/79.3.362","volume":"79","author":"MF Holick","year":"2004","unstructured":"Holick, M. F. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am. J. Clin. Nutr. 79, 362\u2013371 (2004).","journal-title":"Am. J. Clin. Nutr."},{"key":"BFnrendo2014155_CR99","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1210\/jcem-63-4-954","volume":"63","author":"DD Bikle","year":"1986","unstructured":"Bikle, D. D.  et al. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J. Clin. Endocrinol. Metab. 63, 954\u2013959 (1986).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2014155_CR100","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1210\/jcem-61-5-969","volume":"61","author":"DD Bikle","year":"1985","unstructured":"Bikle, D. D., Siiteri, P. K., Ryzen, E. & Haddad, J. G. Serum protein binding of 1,25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels. J. Clin. Endocrinol. Metab. 61, 969\u2013975 (1985).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2014155_CR101","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jsbmb.2009.11.011","volume":"118","author":"YR Lou","year":"2010","unstructured":"Lou, Y. R.  et al. 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. J. Steroid Biochem. Mol. Biol. 118, 162\u2013170 (2010).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"BFnrendo2014155_CR102","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/archinte.168.12.1340","volume":"168","author":"H Dobnig","year":"2008","unstructured":"Dobnig, H.  et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 168, 1340\u20131349 (2008).","journal-title":"Arch. Intern. Med."},{"key":"BFnrendo2014155_CR103","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pbiomolbio.2006.02.001","volume":"92","author":"A Zittermann","year":"2006","unstructured":"Zittermann, A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog. Biophys. Mol. Biol. 92, 39\u201348 (2006).","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"BFnrendo2014155_CR104","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1681\/ASN.V133621","volume":"13","author":"D Zehnder","year":"2002","unstructured":"Zehnder, D.  et al. Synthesis of 1,25-dihydroxyvitamin D3 by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J. Am. Soc. Nephrol. 13, 621\u2013629 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrendo2014155_CR105","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1161\/ATVBAHA.112.248039","volume":"32","author":"P Br\u00f8ndum-Jacobsen","year":"2012","unstructured":"Br\u00f8ndum-Jacobsen, P., Benn, M., Jensen, G. B. & Nordestgaard, B. G. 25-hydroxyvitamin D levels and risk of ischemic heart disease, myocardial infarction, and early death: population-based study and meta-analyses of 18 and 17 studies. Arterioscler. Thromb. Vasc. Biol. 32, 2794\u20132802 (2012).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrendo2014155_CR106","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/CRD.0b013e31821da9a5","volume":"19","author":"SI Sokol","year":"2011","unstructured":"Sokol, S. I., Tsang, P., Aggarwal, V., Melamed, M. L. & Srinivas, V. S. Vitamin D status and risk of cardiovascular events: lessons learned via systematic review and meta-analysis. Cardiol. Rev. 19, 192\u2013201 (2011).","journal-title":"Cardiol. Rev."},{"key":"BFnrendo2014155_CR107","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1161\/CIRCOUTCOMES.112.967604","volume":"5","author":"L Wang","year":"2012","unstructured":"Wang, L.  et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ. Cardiovasc. Qual. Outcomes 5, 819\u2013829 (2012).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"BFnrendo2014155_CR108","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ypmed.2010.06.013","volume":"51","author":"NC Grandi","year":"2010","unstructured":"Grandi, N. C., Breitling, L. P. & Brenner, H. Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies. Prev. Med. 51, 228\u2013233 (2010).","journal-title":"Prev. Med."},{"key":"BFnrendo2014155_CR109","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1161\/HYPERTENSIONAHA.107.087288","volume":"49","author":"JP Forman","year":"2007","unstructured":"Forman, J. P.  et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49, 1063\u20131069 (2007).","journal-title":"Hypertension"},{"key":"BFnrendo2014155_CR110","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.2337\/dc07-0292","volume":"30","author":"C Mattila","year":"2007","unstructured":"Mattila, C.  et al. Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care 30, 2569\u20132570 (2007).","journal-title":"Diabetes Care"},{"key":"BFnrendo2014155_CR111","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/aje\/kwm306","volume":"167","author":"MK Shea","year":"2008","unstructured":"Shea, M. K.  et al. Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am. J. Epidemiol. 167, 313\u2013320 (2008).","journal-title":"Am. J. Epidemiol."},{"key":"BFnrendo2014155_CR112","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/eurheartj\/ehs426","volume":"34","author":"J Tomson","year":"2013","unstructured":"Tomson, J.  et al. Vitamin D and risk of death from vascular and non-vascular causes in the Whitehall study and meta-analyses of 12,000 deaths. Eur. Heart J. 34, 1365\u20131374 (2013).","journal-title":"Eur. Heart J."},{"key":"BFnrendo2014155_CR113","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1046\/j.1523-1755.63.s85.26.x","volume":"85","author":"MP Marco","year":"2003","unstructured":"Marco, M. P.  et al. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int. Suppl. 85, S111\u2013S114 (2003).","journal-title":"Kidney Int. Suppl."},{"key":"BFnrendo2014155_CR114","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/ki.2008.343","volume":"74","author":"M Naves-Diaz","year":"2008","unstructured":"Naves-Diaz, M.  et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int. 74, 1070\u20131078 (2008).","journal-title":"Kidney Int."},{"key":"BFnrendo2014155_CR115","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ndt\/gfg513","volume":"19","author":"T Shoji","year":"2004","unstructured":"Shoji, T.  et al. Lower risk for cardiovascular mortality in oral 1\u03b1-hydroxy vitamin D3 users in a haemodialysis population. Nephrol. Dial. Transplant. 19, 179\u2013184 (2004).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrendo2014155_CR116","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1681\/ASN.2004070573","volume":"16","author":"M Teng","year":"2005","unstructured":"Teng, M.  et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. 16, 1115\u20131125 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrendo2014155_CR117","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/sj.ki.5002451","volume":"72","author":"M Wolf","year":"2007","unstructured":"Wolf, M.  et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 72, 1004\u20131013 (2007).","journal-title":"Kidney Int."},{"key":"BFnrendo2014155_CR118","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/CIRCULATIONAHA.106.673491","volume":"115","author":"J Hsia","year":"2007","unstructured":"Hsia, J.  et al. Calcium\/vitamin D supplementation and cardiovascular events. Circulation 115, 846\u2013854 (2007).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR119","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1161\/HYPERTENSIONAHA.111.00659","volume":"61","author":"JP Forman","year":"2013","unstructured":"Forman, J. P.  et al. Effect of vitamin D supplementation on blood pressure in blacks. Hypertension. 61, 779\u2013785 (2013).","journal-title":"Hypertension."},{"key":"BFnrendo2014155_CR120","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada, T.  et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone. Miner. Res. 19, 429\u2013435 (2004).","journal-title":"J. Bone. Miner. Res."},{"key":"BFnrendo2014155_CR121","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","volume":"119","author":"OM Gutierrez","year":"2009","unstructured":"Gutierrez, O. M.  et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119, 2545\u20132552 (2009).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR122","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Gutierrez","year":"2008","unstructured":"Gutierrez, O. M.  et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359, 584\u2013592 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2014155_CR123","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova, T.  et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305, 2432\u20132439 (2011).","journal-title":"JAMA"},{"key":"BFnrendo2014155_CR124","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.atherosclerosis.2009.05.013","volume":"207","author":"MA Mirza","year":"2009","unstructured":"Mirza, M. A., Larsson, A., Melhus, H., Lind, L. & Larsson, T. E. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207, 546\u2013551 (2009).","journal-title":"Atherosclerosis"},{"key":"BFnrendo2014155_CR125","doi-asserted-by":"publisher","first-page":"640","DOI":"10.7326\/0003-4819-152-10-201005180-00004","volume":"152","author":"BD Parker","year":"2010","unstructured":"Parker, B. D.  et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann. Intern. Med. 152, 640\u2013648 (2010).","journal-title":"Ann. Intern. Med."},{"key":"BFnrendo2014155_CR126","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1093\/eurheartj\/ehr215","volume":"32","author":"S Seiler","year":"2011","unstructured":"Seiler, S.  et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur. Heart J. 32, 2688\u20132696 (2011).","journal-title":"Eur. Heart J."},{"key":"BFnrendo2014155_CR127","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul, C.  et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393\u20134408 (2011).","journal-title":"J. Clin. Invest."},{"key":"BFnrendo2014155_CR128","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1172\/JCI61405","volume":"122","author":"V Shalhoub","year":"2012","unstructured":"Shalhoub, V.  et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J. Clin. Invest. 122, 2543\u20132553 (2012).","journal-title":"J. Clin. Invest."},{"key":"BFnrendo2014155_CR129","doi-asserted-by":"publisher","first-page":"E863","DOI":"10.1152\/ajpendo.00596.2012","volume":"304","author":"CD Touchberry","year":"2013","unstructured":"Touchberry, C. D.  et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am. J. Physiol. Endocrinol. Metab. 304, E863\u2013E873 (2013).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"BFnrendo2014155_CR130","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1681\/ASN.2012090894","volume":"24","author":"JR Dominguez","year":"2013","unstructured":"Dominguez, J. R., Shlipak, M. G., Whooley, M. A. & Ix, J. H. Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes. J. Am. Soc. Nephrol. 24, 647\u2013654 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrendo2014155_CR131","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1463-1326.2006.00610.x","volume":"9","author":"DK Oh","year":"2007","unstructured":"Oh, D. K., Ciaraldi, T. & Henry, R. R. Adiponectin in health and disease. Diabetes Obes. Metab. 9, 282\u2013289 (2007).","journal-title":"Diabetes Obes. Metab."},{"key":"BFnrendo2014155_CR132","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1055\/s-2002-34785","volume":"34","author":"N Stefan","year":"2002","unstructured":"Stefan, N. & Stumvoll, M. Adiponectin\u2014its role in metabolism and beyond. Horm. Metab. Res. 34, 469\u2013474 (2002).","journal-title":"Horm. Metab. Res."},{"key":"BFnrendo2014155_CR133","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jama.2009.976","volume":"302","author":"S Li","year":"2009","unstructured":"Li, S., Shin, H. J., Ding, E. L. & van Dam, R. M. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302, 179\u2013188 (2009).","journal-title":"JAMA"},{"key":"BFnrendo2014155_CR134","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.2337\/diabetes.50.5.1126","volume":"50","author":"K Hotta","year":"2001","unstructured":"Hotta, K.  et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50, 1126\u20131133 (2001).","journal-title":"Diabetes"},{"key":"BFnrendo2014155_CR135","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1161\/01.CIR.103.8.1057","volume":"103","author":"N Ouchi","year":"2001","unstructured":"Ouchi, N.  et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103, 1057\u20131063 (2001).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR136","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1001\/jama.291.14.1730","volume":"291","author":"T Pischon","year":"2004","unstructured":"Pischon, T.  et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291, 1730\u20131737 (2004).","journal-title":"JAMA"},{"key":"BFnrendo2014155_CR137","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1161\/CIRCULATIONAHA.106.618918","volume":"114","author":"N Sattar","year":"2006","unstructured":"Sattar, N.  et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114, 623\u2013629 (2006).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR138","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1161\/01.ATV.0000153090.21990.8c","volume":"25","author":"RS Lindsay","year":"2005","unstructured":"Lindsay, R. S.  et al. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler. Thromb. Vasc. Biol. 25, e15\u2013e16 (2005).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrendo2014155_CR139","doi-asserted-by":"publisher","first-page":"307","DOI":"10.7326\/0003-4819-149-5-200809020-00005","volume":"149","author":"C Heidemann","year":"2008","unstructured":"Heidemann, C.  et al. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann. Intern. Med. 149, 307\u2013316 (2008).","journal-title":"Ann. Intern. Med."},{"key":"BFnrendo2014155_CR140","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.atherosclerosis.2011.07.011","volume":"219","author":"T Pischon","year":"2011","unstructured":"Pischon, T.  et al. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women. Atherosclerosis 219, 322\u2013329 (2011).","journal-title":"Atherosclerosis"},{"key":"BFnrendo2014155_CR141","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1210\/jc.2012-2103","volume":"98","author":"JR Kizer","year":"2013","unstructured":"Kizer, J. R.  et al. Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults. J. Clin. Endocrinol. Metab. 98, 255\u2013263 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2014155_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-2007-958630","volume":"39","author":"W Rathmann","year":"2007","unstructured":"Rathmann, W. & Herder, C. Adiponectin and cardiovascular mortality: evidence for \u201creverse epidemiology\u201d. Horm. Metab. Res. 39, 1\u20132 (2007).","journal-title":"Horm. Metab. Res."},{"key":"BFnrendo2014155_CR143","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.ahj.2011.02.014","volume":"161","author":"SR Wilson","year":"2011","unstructured":"Wilson, S. R.  et al. Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial\u2013Thrombolysis in Myocardial Infarction 22 (PROVE IT\u2013TIMI 22). Am. Heart J. 161, 1147\u20131155 (2011).","journal-title":"Am. Heart J."},{"key":"BFnrendo2014155_CR144","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/oby.2008.564","volume":"17","author":"A Onat","year":"2009","unstructured":"Onat, A., Hergenc, G., Can., G. & Kucukdurmaz, Z. Serum adiponectin confers little protection against diabetes and hypertension in Turkish men. Obesity (Silver Spring) 17, 564\u2013570 (2009).","journal-title":"Obesity (Silver Spring)"},{"key":"BFnrendo2014155_CR145","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.2337\/diabetes.51.7.2306","volume":"51","author":"C Menzaghi","year":"2002","unstructured":"Menzaghi, C.  et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 51, 2306\u20132312 (2002).","journal-title":"Diabetes"},{"key":"BFnrendo2014155_CR146","unstructured":"ADIPOGen Consortium [online], (2014)."},{"key":"BFnrendo2014155_CR147","unstructured":"CARDIoGRAMplusC4D Consortium [online], (2013)."},{"key":"BFnrendo2014155_CR148","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.atherosclerosis.2013.03.034","volume":"229","author":"Z Dastani","year":"2013","unstructured":"Dastani, Z.  et al. The shared allelic architecture of adiponectin levels and coronary artery disease. Atherosclerosis 229, 145\u2013148 (2013).","journal-title":"Atherosclerosis"},{"key":"BFnrendo2014155_CR149","doi-asserted-by":"publisher","first-page":"14478","DOI":"10.1073\/pnas.97.26.14478","volume":"97","author":"AH Kissebah","year":"2000","unstructured":"Kissebah, A. H.  et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc. Natl Acad. Sci. USA 97, 14478\u201314483 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrendo2014155_CR150","doi-asserted-by":"publisher","first-page":"e1002607","DOI":"10.1371\/journal.pgen.1002607","volume":"8","author":"Z Dastani","year":"2012","unstructured":"Dastani, Z.  et al. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet. 8, e1002607 (2012).","journal-title":"PLoS Genet."},{"key":"BFnrendo2014155_CR151","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1172\/JCI29126","volume":"116","author":"T Kadowaki","year":"2006","unstructured":"Kadowaki, T.  et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116, 1784\u20131792 (2006).","journal-title":"J. Clin. Invest."},{"key":"BFnrendo2014155_CR152","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ijcard.2007.12.087","volume":"134","author":"A Coppola","year":"2009","unstructured":"Coppola, A.  et al. Effect of weight loss on coronary circulation and adiponectin levels in obese women. Int. J. Cardiol. 134, 414\u2013416 (2009).","journal-title":"Int. J. Cardiol."},{"key":"BFnrendo2014155_CR153","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1056\/NEJMoa0908359","volume":"362","author":"E Selvin","year":"2010","unstructured":"Selvin, E.  et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N. Engl. J. Med. 362, 800\u2013811 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2014155_CR154","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1001\/archinte.165.16.1910","volume":"165","author":"E Selvin","year":"2005","unstructured":"Selvin, E.  et al. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch. Intern. Med. 165, 1910\u20131916 (2005).","journal-title":"Arch. Intern. Med."},{"key":"BFnrendo2014155_CR155","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.amjmed.2007.03.022","volume":"120","author":"AD Pradhan","year":"2007","unstructured":"Pradhan, A. D., Rifai, N., Buring, J. E. & Ridker, P. M. Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am. J. Med. 120, 720\u2013727 (2007).","journal-title":"Am. J. Med."},{"key":"BFnrendo2014155_CR156","doi-asserted-by":"publisher","first-page":"413","DOI":"10.7326\/0003-4819-141-6-200409210-00006","volume":"141","author":"KT Khaw","year":"2004","unstructured":"Khaw, K. T.  et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann. Intern. Med. 141, 413\u2013420 (2004).","journal-title":"Ann. Intern. Med."},{"key":"BFnrendo2014155_CR157","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/oby.2008.592","volume":"17","author":"RJ Adams","year":"2009","unstructured":"Adams, R. J.  et al. Independent association of HbA1c and incident cardiovascular disease in people without diabetes. Obesity (Silver Spring) 17, 559\u2013563 (2009).","journal-title":"Obesity (Silver Spring)"},{"key":"BFnrendo2014155_CR158","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1371\/journal.pmed.0040263","volume":"4","author":"DA Lawlor","year":"2007","unstructured":"Lawlor, D. A., Fraser, A., Ebrahim, S. & Smith, G. D. Independent associations of fasting insulin, glucose, and glycated haemoglobin with stroke and coronary heart disease in older women. PLoS Med. 4, e263 (2007).","journal-title":"PLoS Med."},{"key":"BFnrendo2014155_CR159","doi-asserted-by":"publisher","first-page":"e000077","DOI":"10.1161\/JAHA.112.000077","volume":"2","author":"JK Pai","year":"2013","unstructured":"Pai, J. K.  et al. Hemoglobin a1c is associated with increased risk of incident coronary heart disease among apparently healthy, nondiabetic men and women. J. Am. Heart Assoc. 2, e000077 (2013).","journal-title":"J. Am. Heart Assoc."},{"key":"BFnrendo2014155_CR160","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/archinte.164.7.757","volume":"164","author":"GJ Blake","year":"2004","unstructured":"Blake, G. J.  et al. Hemoglobin A1c level and future cardiovascular events among women. Arch. Intern. Med. 164, 757\u2013761 (2004).","journal-title":"Arch. Intern. Med."},{"key":"BFnrendo2014155_CR161","doi-asserted-by":"publisher","first-page":"e1000278","DOI":"10.1371\/journal.pmed.1000278","volume":"7","author":"N Sarwar","year":"2010","unstructured":"Sarwar, N.  et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med. 7, e1000278 (2010).","journal-title":"PLoS Med."},{"key":"BFnrendo2014155_CR162","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Sarwar, N.  et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375, 2215\u20132222 (2010).","journal-title":"Lancet"},{"key":"BFnrendo2014155_CR163","doi-asserted-by":"crossref","unstructured":"International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32, 1327\u20131334 (2009).","DOI":"10.2337\/dc09-9033"},{"key":"BFnrendo2014155_CR164","doi-asserted-by":"publisher","first-page":"475","DOI":"10.7326\/0003-4819-141-6-200409210-00014","volume":"141","author":"HC Gerstein","year":"2004","unstructured":"Gerstein, H. C. Glycosylated hemoglobin: finally ready for prime time as a cardiovascular risk factor. Ann. Intern. Med. 141, 475\u2013476 (2004).","journal-title":"Ann. Intern. Med."},{"key":"BFnrendo2014155_CR165","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1046\/j.1464-5491.2000.00228.x","volume":"17","author":"SM Marshall","year":"2000","unstructured":"Marshall, S. M. & Barth, J. H. Standardization of HbA1c measurements\u2014a consensus statement. Diabet. Med. 17, 5\u20136 (2000).","journal-title":"Diabet. Med."},{"key":"BFnrendo2014155_CR166","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1161\/01.STR.0000199034.26345.bc","volume":"37","author":"D Sander","year":"2006","unstructured":"Sander, D.  et al. Combined effects of hemoglobin A1c and C-reactive protein on the progression of subclinical carotid atherosclerosis: the INVADE study. Stroke 37, 351\u2013357 (2006).","journal-title":"Stroke"},{"key":"BFnrendo2014155_CR167","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.3259727","volume":"240","author":"H Vlassara","year":"1988","unstructured":"Vlassara, H., Brownlee, M., Manogue, K. R., Dinarello, C. A. & Pasagian, A. Cachectin\/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240, 1546\u20131548 (1988).","journal-title":"Science"},{"key":"BFnrendo2014155_CR168","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2337\/diacare.26.5.1535","volume":"26","author":"DE King","year":"2003","unstructured":"King, D. E., Mainous, A. G. III, Buchanan, T. A. & Pearson, W. S. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care 26, 1535\u20131539 (2003).","journal-title":"Diabetes Care"},{"key":"BFnrendo2014155_CR169","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1161\/01.CIR.0000029802.88087.5E","volume":"106","author":"S Verma","year":"2002","unstructured":"Verma, S.  et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106, 913\u2013919 (2002).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR170","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1161\/01.CIR.95.7.1783","volume":"95","author":"D Giugliano","year":"1997","unstructured":"Giugliano, D.  et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 95, 1783\u20131790 (1997).","journal-title":"Circulation"},{"key":"BFnrendo2014155_CR171","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(10)60973-7","volume":"375","author":"HC Gerstein","year":"2010","unstructured":"Gerstein, H. C. More insights on the dysglycaemia-cardiovascular connection. Lancet 375, 2195\u20132196 (2010).","journal-title":"Lancet"},{"key":"BFnrendo2014155_CR172","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(96)91420-8","volume":"347","author":"HC Gerstein","year":"1996","unstructured":"Gerstein, H. C. & Yusuf, S. Dysglycaemia and risk of cardiovascular disease. Lancet 347, 949\u2013950 (1996).","journal-title":"Lancet"},{"key":"BFnrendo2014155_CR173","unstructured":"Emerging Risk Factors Collaboration. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA 311, 1225\u20131233 (2014)."},{"key":"BFnrendo2014155_CR174","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler, W. C.  et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393\u2013403 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2014155_CR175","doi-asserted-by":"publisher","first-page":"611","DOI":"10.7326\/0003-4819-142-8-200504190-00009","volume":"142","author":"TJ Orchard","year":"2005","unstructured":"Orchard, T. J.  et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann. Intern. Med. 142, 611\u2013619 (2005).","journal-title":"Ann. Intern. Med."},{"key":"BFnrendo2014155_CR176","doi-asserted-by":"publisher","first-page":"888","DOI":"10.2337\/diacare.28.4.888","volume":"28","author":"R Ratner","year":"2005","unstructured":"Ratner, R.  et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 28, 888\u2013894 (2005).","journal-title":"Diabetes Care"},{"key":"BFnrendo2014155_CR177","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S2213-8587(14)70057-9","volume":"2","author":"G Li","year":"2014","unstructured":"Li, G.  et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2, 474\u2013480 (2014).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"BFnrendo2014155_CR178","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Gerstein, H. C.  et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J.Med. 358, 2545\u20132559 (2008).","journal-title":"N. Engl. J.Med."},{"key":"BFnrendo2014155_CR179","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/j.1463-1326.2010.01255.x","volume":"12","author":"EE Wright Jr.","year":"2010","unstructured":"Wright, E. E. Jr., Stonehouse, A. H. & Cuddihy, R. M. In support of an early polypharmacy approach to the treatment of type 2 diabetes. Diabetes Obes. Metab. 12, 929\u2013940 (2010).","journal-title":"Diabetes Obes. Metab."},{"key":"BFnrendo2014155_CR180","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","volume":"344","author":"J Tuomilehto","year":"2001","unstructured":"Tuomilehto, J.  et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343\u20131350 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2014155_CR181","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0140-6736(06)69701-8","volume":"368","author":"J Lindstrom","year":"2006","unstructured":"Lindstrom, J.  et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368, 1673\u20131679 (2006).","journal-title":"Lancet"},{"key":"BFnrendo2014155_CR182","doi-asserted-by":"crossref","unstructured":"[No authors listed] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837\u2013853 (1998).","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"BFnrendo2014155_CR183","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMicm066227","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel, A.  et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560\u20132572 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2014155_CR184","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth, W.  et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129\u2013139 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2014155_CR185","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1089\/ars.2009.2793","volume":"12","author":"AP Levy","year":"2010","unstructured":"Levy, A. P.  et al. Haptoglobin: basic and clinical aspects. Antioxid. Redox Signal. 12, 293\u2013304 (2010).","journal-title":"Antioxid. Redox Signal."},{"key":"BFnrendo2014155_CR186","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jacc.2013.04.079","volume":"62","author":"LE Cahill","year":"2013","unstructured":"Cahill, L. E.  et al. Currently available versions of genome-wide association studies cannot be used to query the common haptoglobin copy number variant. J. Am. Coll. Cardiol. 62, 860\u2013861 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrendo2014155_CR187","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/clinchem\/42.10.1589","volume":"42","author":"MR Langlois","year":"1996","unstructured":"Langlois, M. R. & Delanghe, J. R. Biological and clinical significance of haptoglobin polymorphism in humans. Clin. Chem. 42, 1589\u20131600 (1996).","journal-title":"Clin. Chem."},{"key":"BFnrendo2014155_CR188","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.atherosclerosis.2003.10.014","volume":"172","author":"AP Levy","year":"2004","unstructured":"Levy, A. P.  et al. Haptoglobin phenotype and prevalent coronary heart disease in the Framingham offspring cohort. Atherosclerosis 172, 361\u2013365 (2004).","journal-title":"Atherosclerosis"},{"key":"BFnrendo2014155_CR189","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0021-9150(00)00690-0","volume":"157","author":"D De Bacquer","year":"2001","unstructured":"De Bacquer, D.  et al. Haptoglobin polymorphism as a risk factor for coronary heart disease mortality. Atherosclerosis 157, 161\u2013166 (2001).","journal-title":"Atherosclerosis"},{"key":"BFnrendo2014155_CR190","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1161\/01.RES.0000156653.05853.b9","volume":"96","author":"R Asleh","year":"2005","unstructured":"Asleh, R., Guetta, J., Kalet-Litman, S., Miller-Lotan, R. & Levy, A. P. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ. Res. 96, 435\u2013441 (2005).","journal-title":"Circ. Res."},{"key":"BFnrendo2014155_CR191","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1161\/01.RES.0000251741.65179.56","volume":"99","author":"R Asleh","year":"2006","unstructured":"Asleh, R.  et al. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ. Res. 99, 1419\u20131425 (2006).","journal-title":"Circ. Res."},{"key":"BFnrendo2014155_CR192","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1161\/01.RES.0000076889.23082.F1","volume":"92","author":"R Asleh","year":"2003","unstructured":"Asleh, R.  et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ. Res. 92, 1193\u20131200 (2003).","journal-title":"Circ. Res."},{"key":"BFnrendo2014155_CR193","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jacc.2012.09.063","volume":"61","author":"LE Cahill","year":"2013","unstructured":"Cahill, L. E.  et al. Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J. Am. Coll. Cardiol. 61, 728\u2013737 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrendo2014155_CR194","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0735-1097(02)02534-2","volume":"40","author":"AP Levy","year":"2002","unstructured":"Levy, A. P.  et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J. Am. Coll. Cardiol. 40, 1984\u20131990 (2002).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrendo2014155_CR195","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMoa1006524","volume":"364","author":"HC Gerstein","year":"2011","unstructured":"Gerstein, H. C.  et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N. Engl. J. Med. 364, 818\u2013828 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2014155_CR196","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1751-553X.2007.00898.x","volume":"29","author":"K Carter","year":"2007","unstructured":"Carter, K. & Worwood, M. Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases. Int. J. Lab. Hematol. 29, 92\u2013110 (2007).","journal-title":"Int. J. Lab. Hematol."},{"key":"BFnrendo2014155_CR197","doi-asserted-by":"publisher","first-page":"136","DOI":"10.7326\/M13-2841","volume":"160","author":"AJ Vickers","year":"2014","unstructured":"Vickers, A. J. & Pepe, M. Does the net reclassification improvement help us evaluate models and markers? Ann. Intern. Med. 160, 136\u2013137 (2014).","journal-title":"Ann. Intern. Med."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrendo.2014.155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrendo.2014.155","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrendo.2014.155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T05:11:26Z","timestamp":1650345086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrendo.2014.155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,2]]},"references-count":197,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["BFnrendo2014155"],"URL":"https:\/\/doi.org\/10.1038\/nrendo.2014.155","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,2]]},"assertion":[{"value":"2 September 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.K.J. and E.B.R. have received unrestricted research support from Roche to measure HDL subtypes in the Multi-Ethnic Study of Atherosclerosis. M.K.J and E.B.R are listed as co-inventors on a patent application filed by Harvard University for HDL ApoC-III (US Patent Application 13\/046,682, filed March 11, 2011: \u201cAssay and prediction of cardiovascular risk based on HDL subtypes according to apoC-III\u201d.). M.L.B., L.E.C., I.A. and K.J.M. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}